万咏梅,王富珍,郑徽,张国民,张卫,姚军,崔富强

• 1:中国疾病预防控制中心免疫规划中心
• 2:北京市疾病预防控制中心
• 3:浙江省疾病预防控制中心
• 4:北京大学公共卫生学院

摘要(Abstract)：

目的比较成人三种乙型肝炎疫苗(Hepatitis B vaccine,HepB)—汉逊酵母HepB (HepB-HP)、CHO细胞HepB(HepB-CHO)和酿酒酵母HepB(HepB-BC)不同免疫程序的免疫原性。方法在北京市和浙江省招募20-49岁成人,分为10μgHepB-HP、10μgHepB-CHO、10μgHepB-BC、20μgHepB-BC四个接种组,每组按HepB不同基础免疫程序接种,检测接种后1-2月乙型肝炎表面抗体(HBsAb),比较抗体阳性率和几何平均浓度(GMC)。结果四个组分别纳入研究对象430名、1 513名、1 350名、256名。10μgHepB-HP组0-1-2月(month,m)、0-1-3m、0-1-6m、0-1-12m程序HBsAb阳性率分别为71.57%、97.37%、100%、91.58%(x2=65.89,P<0.001),GMC(mIU/mL)分别为116.70、381.27、915.36、918.23(F=32.01,P<0.001);10μgHepB-CHO组0-1-3m、0-1-6m、0-1-12m程序HBsAb阳性率分别为83.65%、88.55%、88.17%(x2=6.78,P=0.034),GMC(mIU/mL)分别为144.94、328.37、296.14(H=56.42,P<0.001);10μg HepB-BC组0-1-2m、0-1-3m、0-1-6m、0-1-12m程序HBsAb阳性率分别为81.34%、85.19%、87.07%、79.54%(x2=8.63,P=0.035),GMC(mIU/mL)分别为114.41、170.65、329.21、475.13(H=71.97,P<0.001);20μgHepB-BC组0-1-2m、0-1-3m、0-1-6m程序HBsAb阳性率分别为83.02%、100%、96.46%(x2=20.95,P<0.001),GMC(mIU/mL)分别为167.03、949.83、1688.67(F=27.01,P<0.001)。结论 20-49岁成人接种HepB具有良好的免疫原性,以0-1-6m、0-1-12m程序较好。

关键词(KeyWords)： 乙型肝炎疫苗;免疫程序;免疫原性

Abstract:

Keywords:

基金项目(Foundation): 中国成人高危人群和社区人群乙肝疫苗优化免疫策略研究（2018ZX10721202）

作者(Author): 万咏梅,王富珍,郑徽,张国民,张卫,姚军,崔富强

参考文献(References)：

• [1]WHO.Hepat it is B f act sheets[EB/OL].(2018-07-18)[2019-06-22].http://wwwwhoint/news-room/fact-sheets/detail/hepatitis-b.
• [2]RAZAVI-SHEARER D,GAMKRELIDZE I,NGUYENMH,et al.Global prevalence,treatment,and prevention of hepatitis B virus infection in 2016:a modelling study[J].The Lancet Gastroenterology&Hepatology,2018,3(6):383-403.
• [3]LU FM,LI T,LIU S,et al.Epidemiology and prevention of hepatitis B virus infection in China[J].J Viral Hepat,2010,17(Suppl 1):4-9.
• [4]CUI F,SHEN L,LI L,e t al.Prevent ion of chronic hepatitis B af ter 3 decades of escalating vaccination policy,China[J].Emerg Infect Dis,2017,23(5):765-772.
• [5]崔富强,张国民,孙校金.中国15~59岁人群乙型肝炎病毒感染易感性分析[J].江苏预防医学,2013,24(4):1-3.CUI F,ZHANG G,SUN X.Analysis on susceptibility of hepatitis B virus infection among population aged between 15 and59 in China[J].Jiangsu Journal of Preventive Medicine,2013,24(4):1-3.
• [6]YANG L,YAO J,LI J,et al.Suitable hepatitis B vaccine f or adult immunization in China[J].Immunol Res,2016,64:242-250.
• [7]张卫,林长缨,韩莉莉,等.不同剂量国产重组酵母乙型肝炎疫苗成年人免疫效果及影响因素研究[J].中华流行病学杂志,2010,31(7):767-770.ZHANG Wei,LIN Changyin,HAN Lili,et al.Study of immuno-effects and influencing factors of Chinese Hamster Ovary(CHO)cell hepatitis Bvaccine among adults,under different dosages[J].Chin JEpidemiol,2010,31(7):767-770.
• [8]聂黎,庞星火,张政,等.不同种类和剂量乙型肝炎疫苗成年人快速免疫效果观察[J].中华流行病学杂志,2017,38(9):1151-1155.NIE Li,PANG Xinghuo,ZHANG Zheng,et al.Effectiveness of rapid hepatitis B vaccination with diff erent vaccine dosages and types in adults[J].Chin JEpidemiol,2017,38(9):1151-1155.
• [9]REN JJ,DAI XW,JIANG ZG,et al.Immunological effects of a 10-mug dose of domestic hepatitis B vaccine in adults[J].J Zhejiang Univ Sci B,2012,13(11):948-954.
• [10]WU Z,BAO H,YAO J,et al.Suitable hepatitis B vaccine for adult immunization in China:a systematic review and metaanalysis[J].Hum Vaccin Immunother,2019,15(1):220-227.
• [11]YAO J,QIU Y,CHEN Y,et al.Opt imal vaccinat ion program for healthy adults in China[J].Human Vaccines&Immunotherapeutics,2015,11(10):2389-2396.
• [12]HERNANDEZ-BERNAL F,AGUILAR-BETANCOURTA,ALJOVIN V,et al.Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults[J].Hum Vaccin,2011,7(10):1026-1036.
• [13]YANG S,TIAN G,CUI Y,et al.Factors inf luencing immunologic response to hepatitis B vaccine in adults[J].Sci Rep,2016,6(27251):1-12.
• [14]WHO.Hepatitis B vaccines:WHO position paper[J].Weekly Epidemiological Record,2017,27(92):369-392.
• [15]LEURIDAN E,VAN DAMME P.Hepatitis B and the need for a booster dose[J].Clin Infect Dis,2011,53(1):68-75.
• [16]KAO J-H,CHEN D-S.Hepatitis B vaccination:to boost or not to boost?[J].The Lancet,2005,366(9494):1337-1338.
• [17]POOROLAJAL J,MAHMOODI M,MAJDZADEH R,et al.Long-term protection provided by hepatitis B vaccine and need for booster dose:a meta-analysis[J].Vaccine,2010,28(3):623-631.
• [18]CHIARAMONTE M,MAJORIT S,NGATCHU T,et al.Two dif f erent dosages of yeast derived recombinant hepatitis B vaccines_a comparison of immunogenicity[J].Vaccine,1996,14(2):135-137.
• [19]ZHANG L,YAN B,LV J,et al.Antibody response to hepatitis B vaccine is independently associated with hepatitis B breakthrough infection among adults:results f rom a three-year follow-up study in China[J].Vaccine,2018,36(2018):2207-2212.
• [20]VAN DER MEEREN O,CRASTA P,CHEUVART B,et al.Characterization of an age-response relationship to GSK’s recombinant hepatitis B vaccine in healthy adults:an integrated analysis[J].Hum Vaccin Immunother,2015,11(7):1726-1729.
• [21]ZHENG H,WANG FZ,ZHANG GM,et al.An economic analysis of adult hepatitis B vaccination in China[J].Vaccine,2015,33(48):6831-6839.